

August 31, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of completion of SHED Master Cell Bank in compliance with GMP

Tokyo, August 31, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that Master Cell Bank (MCB) of SHED (Stem cells from Human Exfoliated Deciduous teeth) passed final verification tests and MCB of SHED in compliance with GMP was completed.

Under the business alliance agreement with Nikon Corporation, KWB has been working on the establishment of a manufacturing MCB of SHED with Nikon CeLL innovation (a wholly owned subsidiary of Nikon Corporation, providing cell and gene therapy manufacturing service of regenerative medicine) as an essential component in creating regenerative medicine products. For delivering the world's first cell therapy and gene therapy products with SHED to patients, KWB will promote the development of regenerative medicine products utilizing MCB of SHED not only to create regenerative medicine products with SHED as a raw material but also SHED-derived exosome and new treatment methods by combining SHED with gene therapy.

Unlike small molecule drugs manufactured by chemical synthesis, since cell therapy uses cells which are not always constant and affected by various environments, it is not easy to establish a manufacturing process and maintain the quality of SHED as a raw material. As KWB has to guarantee a stable supply and the quality of SHED to create regenerative medicines utilizing SHED, KWB launched Chivo Net, Children Volunteer Network for Future Medical, for deciduous teeth donation and collaborated with the University of Tokyo Hospital and Showa University Dental Hospital to collect deciduous teeth from donors. As a result, KWB accomplished the manufacturing process of a high-quality SHED MCB under this series of systems.

As part of an important growth strategy for early corporate value improvement in the Mid-Term Strategic Plan KWB 2.0 announced on May 12, 2022, KWB has been striving for the research and development of the cell therapy (regenerative medicine) business focusing on pediatric, rare and intractable diseases. As the MCB of SHED is used as a seed cell during the manufacture of these regenerative medicine products, it is essential for the practical application, manufacture, and stable supply of regenerative medicine products. With the reliable SHED master cell bank, KWB will

accelerate the research and development activities of the cell therapy (regenerative medicine) pipeline in collaboration with academia and companies.

The financial impact on the business results for the fiscal year ending March 2023 is expected to be minimal.

About Nikon CeLL innovation Co., Ltd.

Nikon CeLL innovation Co., Ltd. (NCLi) operates reliable Cell and Gene therapy facility in Japan, offers broad selection of contract development and manufacturing (CDMO) services.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com